U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07377435) titled 'DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM' on Jan. 22.
Brief Summary: This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma.
The names of the study drugs involved in this study are:
* DC/MM fusion vaccine (a type of personalized cancer vaccine)
* Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Refractory Mult...